This page shows the latest mRNA-1273 news and features for those working in and with pharma, biotech and healthcare.
Moderna said in a statement yesterday that it is ‘fully’ cooperating with an investigation into possible allergic reactions at a vaccination centre in the US administering its mRNA-based COVID-19 ... s mRNA-based vaccine.
On Wednesday, the European Commission granted Moderna’s COVID-19 vaccine, initially called mRNA-1273, a conditional marketing authorisation to prevent the disease in people aged 18 years and older.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) met to discuss the Moderna vaccine, mRNA-1273, on Monday. ... older. Following this recommendation, the European Commission (EC) is likely to grant mRNA-1273 a formal conditional marketing
Moderna’s European manufacturing partner Lonza received authorisation from Swiss regulators last week to begin producing mRNA-1273 at its plant in Switzerland.
The US government has agreed to purchase 200 million doses of mRNA-1273 with options to purchase another 300 million doses. ... The European Commission has already approved a contract for an initial 80 million doses of mRNA-1273, with a further option to
Following this recommendation, the FDA has formally granted mRNA-1273 a EUA for the prevention of COVID-19 in individuals aged 18 years and older. ... Following the EUA, Moderna will now begin to deliver the first mRNA-1273 doses to the US government
More from news
Approximately 14 fully matching, plus 21 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...